Last reviewed · How we verify
Xeloda
At a glance
| Generic name | Xeloda |
|---|---|
| Also known as | Capecitabine, Capetabine, capecitabine, X |
| Sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| Target | Thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Lymph Node Positive Colorectal Carcinoma
- Malignant tumor of stomach
- Metastasis from malignant tumor of colon
- Metastatic Breast Carcinoma
Common side effects
- Diarrhea
- Nausea
- Stomatitis
- Vomiting
- Abdominal Pain
- Fatigue
- Pyrexia
- Alopecia
- Rash
- Dyspepsia
- Constipation
- Upper Abdominal Pain
Key clinical trials
- Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers (PHASE1)
- A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) (PHASE3)
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) (PHASE3)
- Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body (PHASE3)
- Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xeloda CI brief — competitive landscape report
- Xeloda updates RSS · CI watch RSS
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins portfolio CI